Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with Nab-paclitaxel in ER+/HER2- Advanced Breast Cancer
NCT04132817Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab and ipilimumab in breast cancer (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Incidence of Adverse Events up to 3 years, Incidence of Serious Adverse Events up to 3 years and 3 more. Started Sep 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04132817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04132817.